491 related articles for article (PubMed ID: 37544827)
1. Safety profile and SARS-CoV-2 breakthrough infections among HCWs receiving anti-SARS-CoV-2 and influenza vaccines simultaneously: an Italian observational study.
Moscara L; Venerito V; Martinelli A; Di Lorenzo A; Toro F; Violante F; Tafuri S; Stefanizzi P
Vaccine; 2023 Aug; 41(38):5655-5661. PubMed ID: 37544827
[TBL] [Abstract][Full Text] [Related]
2. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
3. Association of Receiving a Fourth Dose of the BNT162b Vaccine With SARS-CoV-2 Infection Among Health Care Workers in Israel.
Cohen MJ; Oster Y; Moses AE; Spitzer A; Benenson S;
JAMA Netw Open; 2022 Aug; 5(8):e2224657. PubMed ID: 35917125
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study.
Izikson R; Brune D; Bolduc JS; Bourron P; Fournier M; Moore TM; Pandey A; Perez L; Sater N; Shrestha A; Wague S; Samson SI
Lancet Respir Med; 2022 Apr; 10(4):392-402. PubMed ID: 35114141
[TBL] [Abstract][Full Text] [Related]
5. Risk of Vaccine Breakthrough SARS-CoV-2 Infection and Associated Factors in Healthcare Workers of Trieste Teaching Hospitals (North-Eastern Italy).
Basso P; Negro C; Cegolon L; Larese Filon F
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215930
[No Abstract] [Full Text] [Related]
6. Immune response to one dose of BNT162b2 mRNA Covid-19 vaccine followed by SARS-CoV-2 infection: An Italian prospective observational study.
Stefanizzi P; Larocca AMV; Martinelli A; Soldano S; Dell'Aera M; Migliore G; Germinario CA; Vimercati L; Tafuri S; Bianchi FP
Vaccine; 2022 Mar; 40(12):1805-1809. PubMed ID: 35190212
[TBL] [Abstract][Full Text] [Related]
7. Durability of anti-spike antibodies after vaccination with mRNA SARS-CoV-2 vaccine is longer in subjects with previous infection: could the booster dose be delayed?
Stellini R; Gianello R; Gomarasca W
Infection; 2022 Dec; 50(6):1573-1577. PubMed ID: 35391649
[TBL] [Abstract][Full Text] [Related]
8. Co-administration of SARS-CoV-2 and influenza vaccines in healthcare workers: Results of two vaccination campaigns in a large teaching hospital in Rome.
Pascucci D; Lontano A; Regazzi L; Marziali E; Nurchis MC; Raponi M; Vetrugno G; Moscato U; Cadeddu C; Laurenti P
Hum Vaccin Immunother; 2023 Dec; 19(3):2287282. PubMed ID: 38016914
[TBL] [Abstract][Full Text] [Related]
9. Reactogenicity of Simultaneous COVID-19 mRNA Booster and Influenza Vaccination in the US.
Hause AM; Zhang B; Yue X; Marquez P; Myers TR; Parker C; Gee J; Su J; Shimabukuro TT; Shay DK
JAMA Netw Open; 2022 Jul; 5(7):e2222241. PubMed ID: 35838667
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
11. Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up.
Ponticelli D; Madotto F; Conti S; Antonazzo IC; Vitale A; Della Ragione G; Romano ML; Borrelli M; Schiavone B; Polosa R; Ferrara P; Mantovani LG
Intern Emerg Med; 2022 Mar; 17(2):481-486. PubMed ID: 34637084
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.
Lazarus R; Baos S; Cappel-Porter H; Carson-Stevens A; Clout M; Culliford L; Emmett SR; Garstang J; Gbadamoshi L; Hallis B; Harris RA; Hutton D; Jacobsen N; Joyce K; Kaminski R; Libri V; Middleditch A; McCullagh L; Moran E; Phillipson A; Price E; Ryan J; Thirard R; Todd R; Snape MD; Tucker D; Williams RL; Nguyen-Van-Tam JS; Finn A; Rogers CA;
Lancet; 2021 Dec; 398(10318):2277-2287. PubMed ID: 34774197
[TBL] [Abstract][Full Text] [Related]
13. Antibody responses and SARS-CoV-2 infection after BNT162b2 mRNA booster vaccination among healthcare workers in Japan.
Igari H; Asano H; Murata S; Yoshida T; Kawasaki K; Kageyama T; Ikeda K; Koshikawa H; Okuda Y; Urushihara M; Chiba H; Yahaba M; Taniguchi T; Matsushita K; Yoshino I; Yokote K; Nakajima H
J Infect Chemother; 2022 Nov; 28(11):1483-1488. PubMed ID: 35870791
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of MRNA booster vaccine among healthcare workers in New York City during the Omicron surge, December 2021 to January 2022.
Robilotti EV; Whiting K; Lucca A; Poon C; Jani K; McMillen T; Freeswick S; Korenstein D; Babady NE; Seshan VE; Kamboj M
Clin Microbiol Infect; 2022 Dec; 28(12):1624-1628. PubMed ID: 35931373
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics of healthcare workers with SARS-CoV-2 infection after vaccination with BNT162b2 vaccine.
Lombardi A; Renisi G; Consonni D; Oggioni M; Bono P; Uceda Renteria S; Piatti A; Pesatori AC; Castaldi S; Muscatello A; Riboldi L; Ceriotti F; Gori A; Bandera A
BMC Infect Dis; 2022 Jan; 22(1):97. PubMed ID: 35090388
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of third dose of anti-SARS-CoV-2 vaccine co-administered with influenza vaccine: An open question.
Stefanizzi P; Tafuri S; Bianchi FP
Hum Vaccin Immunother; 2022 Nov; 18(6):2094653. PubMed ID: 35820047
[TBL] [Abstract][Full Text] [Related]
17. The effect of a third BNT162b2 vaccine on breakthrough infections in health care workers: a cohort analysis.
Oster Y; Benenson S; Nir-Paz R; Buda I; Cohen MJ
Clin Microbiol Infect; 2022 May; 28(5):735.e1-735.e3. PubMed ID: 35143997
[TBL] [Abstract][Full Text] [Related]
18. Impact of prior infection status on antibody response to the BNT162b2 mRNA COVID-19 vaccine in healthcare workers at a COVID-19 referral hospital in Milan, Italy.
Milazzo L; Pezzati L; Oreni L; Kullmann C; Lai A; Gabrieli A; Bestetti G; Beschi C; Conti F; Ottomano C; Gervasoni C; Meroni L; Galli M; Antinori S; Ridolfo AL
Hum Vaccin Immunother; 2021 Dec; 17(12):4747-4754. PubMed ID: 35086438
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of BNT162b2 mRNA Coronavirus Disease 2019 (COVID-19) Vaccine Against Acquisition of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Among Healthcare Workers in Long-Term Care Facilities: A Prospective Cohort Study.
Muhsen K; Maimon N; Mizrahi A; Bodenheimer O; Cohen D; Maimon M; Grotto I; Dagan R
Clin Infect Dis; 2022 Aug; 75(1):e755-e763. PubMed ID: 34698808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
